Chromosomal microarray analysis in fetuses with an isolated congenital heart defect: A retrospective, nationwide, multicenter study in France.


Journal

Prenatal diagnosis
ISSN: 1097-0223
Titre abrégé: Prenat Diagn
Pays: England
ID NLM: 8106540

Informations de publication

Date de publication:
05 2019
Historique:
received: 17 12 2018
revised: 05 03 2019
accepted: 15 03 2019
pubmed: 22 3 2019
medline: 25 4 2020
entrez: 22 3 2019
Statut: ppublish

Résumé

Congenital heart defects (CHDs) may be isolated or associated with other malformations. The use of chromosome microarray (CMA) can increase the genetic diagnostic yield for CHDs by between 4% and 10%. The objective of this study was to evaluate the value of CMA after the prenatal diagnosis of an isolated CHD. In a retrospective, nationwide study performed in France, we collected data on all cases of isolated CHD that had been explored using CMAs in 2015. A total of 239 fetuses were included and 33 copy number variations (CNVs) were reported; 19 were considered to be pathogenic, six were variants of unknown significance, and eight were benign variants. The anomaly detection rate was 10.4% overall but ranged from 0% to 16.7% as a function of the isolated CHD in question. The known CNVs were 22q11.21 deletions (n = 10), 22q11.21 duplications (n = 2), 8p23 deletions (n = 2), an Alagille syndrome (n = 1), and a Kleefstra syndrome (n = 1). The additional diagnostic yield was clinically significant (3.1%), even when anomalies in the 22q11.21 region were not taken into account. Hence, patients with a suspected isolated CHD and a normal karyotype must be screened for chromosome anomalies other than 22q11.21 duplications and deletions.

Identifiants

pubmed: 30896039
doi: 10.1002/pd.5449
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

464-470

Informations de copyright

© 2019 John Wiley & Sons, Ltd.

Auteurs

Marguerite Hureaux (M)

Service d'Histologie-Embryologie-Cytogénétique, Hôpital Necker-Enfants Malades, APHP, Paris, France.

Sarah Guterman (S)

EA7404-GIG, UFR des sciences de la Santé Simone Veil, UVSQ, Montigny le Bretonneux, France.
Service de Gynécologie Obstétrique, CHI de Poissy, St Germain, Poissy, France.

Bérénice Hervé (B)

EA7404-GIG, UFR des sciences de la Santé Simone Veil, UVSQ, Montigny le Bretonneux, France.
Unité de Cytogénétique, CHI de Poissy St Germain, Poissy, France.

Marianne Till (M)

Service de Génétique, Hospices civils de Lyon, Lyon, France.

Sylvie Jaillard (S)

Service de Cytogénétique, CHU de Rennes, Rennes, France.

Sylvie Redon (S)

Laboratoire de Cytogénétique, Cytologie et Biologie de la Reproduction, CHRU, Brest, France.

Myléne Valduga (M)

Service de Génétique, CHU Nancy-Brabois, Nancy, France.

Charles Coutton (C)

Service de Génétique Chromosomique, Hôpital Couple-Enfant, CHU Grenoble Alpes, La Tronche, France.
Equipe GETI - IAB, INSERM U1209, Université Grenoble-Alpes, La Tronche, France.

Chantal Missirian (C)

Département de Génétique Médicale, CHU Timone Enfants, APHM, Marseille, France.

Fabienne Prieur (F)

Service de Génétique Clinique Chromosomique Moléculaire, CHU Saint-Etienne, Saint-Etienne, France.

Brigitte Simon-Bouy (B)

Génétique Constitutionnelle, Laboratoire de Biologie, Centre Hospitalier de Versailles, Le Chesnay, France.

Claire Beneteau (C)

Service de Génétique Médicale, CHU Nantes, Nantes, France.

Paul Kuentz (P)

Service de Génétique Biologique, CHRU Besançon, Besançon, France.

Caroline Rooryck (C)

CHU de Bordeaux, Service de Génétique Médicale, Bordeaux, France.

Nicolas Gruchy (N)

Service de Génétique, CHU Caen, Caen, France.

Nathalie Marle (N)

Laboratoire de Génétique Chromosomique et Moléculaire, CHU Dijon, Dijon, France.

Morgane Plutino (M)

Service de Génétique, CHU Nice, Nice, France.

Lucie Tosca (L)

Service d'Histologie Embryologie Cytogénétique, Hôpital Antoine Béclère, Clamart, France.

Celine Dupont (C)

Service de Cytogénétique, APHP Hôpital Robert Debré, Paris, France.

Jacques Puechberty (J)

Service de Génétique, CHU Montpellier, Montpellier, France.

Caroline Schluth-Bolard (C)

Service de Génétique, Hospices civils de Lyon, Lyon, France.

Laurent Salomon (L)

Service d'Obstétrique, Hôpital Necker-Enfants Malades, APHP, Paris, France.

Damien Sanlaville (D)

Service de Génétique, Hospices civils de Lyon, Lyon, France.

Valérie Malan (V)

Service d'Histologie-Embryologie-Cytogénétique, Hôpital Necker-Enfants Malades, APHP, Paris, France.
Sorbonne Paris Cité, Université Paris Descartes, Paris, France.

François Vialard (F)

EA7404-GIG, UFR des sciences de la Santé Simone Veil, UVSQ, Montigny le Bretonneux, France.
Unité de Cytogénétique, CHI de Poissy St Germain, Poissy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH